Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia

Perbellini, Omar; Falisi, Erika; Giaretta, Ilaria; Boscaro, Elisa; Novella, Elisabetta; Facco, Monica; Fortuna, Stefania; Finotto, Silvia; Amati, Eliana; Maniscalco, Francesco; Montaldi, A.; Alghisi, Alberta; Aprili, Fiorenza; Bonaldi, Laura; Paolini, Rossella; Scupoli, Maria Teresa; Trentin, Livio; Ambrosetti, Achille; Semenzato, Gianpietro; Pizzolo, Giovanni; Rodeghiero, Francesco; Visco, Carlo

doi:10.3324/haematol.2013.096362

Cited by 33 publications

(28 citation statements)

References 29 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfavorable prognostic factors include male gender, an initial white blood cell count above 35 × 10 9 /L, lymphocyte doubling time (LDT) of less than six months, a diffuse histological pattern in bone marrow infiltration 35 and elevated levels of beta-2 microglobulin, LDH, serum thymidine, and serum CD23 at diagnosis 36 . As previously discussed, high expressions of CD38, 29 CD49d, 37 CD305, 38 and ZAP-70 protein detected by flow cytometry are also prognostic markers 31 . However, these markers are no more sensitive than clinical staging for determining tumor burden and predicting disease progression.…”

Section: Prognosismentioning

confidence: 99%

Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia

Rodrigues

Gonçalves

Ikoma

et al. 2016

Revista Brasileira de Hematologia e Hemoterapia

View full text Add to dashboard Cite

Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19+, CD5+ and CD23+. The lymphocytes usually infiltrate the bone marrow, peripheral blood, lymph nodes, and spleen. The diagnosis is established by immunophenotyping circulating B-lymphocytes, and prognosis is defined by two staging systems (Rai and Binet) established by physical examination and blood counts, as well as by several biological and genetic markers. In this update, we present the recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia for the diagnosis and treatment of chronic lymphocytic leukemia. The following recommendations are based on an extensive literature review with the aim of contributing to more uniform patient care in Brazil and possibly in other countries with a similar social–economic profile.

show abstract

Section: Prognosismentioning

confidence: 99%

Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia

Rodrigues

Gonçalves

Ikoma

et al. 2016

Revista Brasileira de Hematologia e Hemoterapia

View full text Add to dashboard Cite

show abstract

“…Clinical significance of the expression of leukocyte‐associated immunoglobulin‐like receptor‐1 (LAIR1, CD305), an inhibitor of B‐cell receptor‐mediated signaling, has been reported in chronic lymphocytic leukemia. Downregulation of LAIR1 was observed in high‐risk CLL, respectively . According to gene expression‐activated B cells, CD22 low CD25 + seems to be genetically closer to WM‐BC, as GEP analysis showed only 51 downregulated genes in WM‐BC …”

Section: Wm B‐cell Clone Molecular Biology: Similarity To Normal B Cellsmentioning

confidence: 98%

Waldenström′s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection

Growková

Kryukova

Kufova

et al. 2017

European J of Haematology

View full text Add to dashboard Cite

Waldenström′s macroglobulinemia (WM) is a complex disease characterized by apparent morphological heterogeneity within the malignant clonal cells representing a continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. At the molecular level, the neoplastic B cell-derived clone has undergone somatic hypermutation, but not isotype switching, and retains the capability of plasmacytic differentia- | REGULATION OF B-CELL DEVELOPMENT: WHERE IS THE MISTAKE?Tumor cells of Waldenström′s macroglobulinemia derive from B lymphocyte during its development and show a wide morphological heterogeneity. 12 In general, the process of B lymphocyte development is regulated by several transcription factors and is accompa-

show abstract

“…However, based on clinical (e.g., stage and doubling time), phenotypic, and genetic features, it can be completely indolent or quite aggressive. Specifically, the overall expression of CD38, ZAP70, LAIR1, and CD49d biomarkers, though not univocally, indicates an activation of the leukemic B cell and it is related to a worse outcome . In addition, immunohistological analyses have demonstrated that the identification of abundant proliferating centers is associated to a worse behavior .…”

mentioning

confidence: 99%

IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia

Piccaluga

Agostinelli

Righi

et al. 2017

APMIS

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Its clinical course is typically indolent; however, based on a series of pathobiological, clinical, genetic, and phenotypic parameters, patient survival varies from less than 5 to more than 20 years. In this paper, we show for the first time that the expression of the interferon-inducible DNA sensor IFI16, a member of the PYHIN protein family involved in proliferation inhibition and apoptosis regulation, is associated with the clinical outcome in CLL. We studied 99 CLLs cases by immunohistochemistry and 10 CLLs cases by gene expression profiling. We found quite variable degrees of IFI16 expression among CLLs cases. Noteworthy, we observed that a reduced IFI16 expression was associated with a very poor survival, but only in cases with ZAP70/CD38 expression. Furthermore, we found that IFI16 expression was associated with a specific gene expression signature. As IFI16 can be easily detected by immunohistochemistry or flow cytometry, it may become a part of phenotypic screening in CLL patients if its prognostic role is confirmed in independent series.

show abstract

Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia

Abstract: ABSTRACTexpressed in early stages of CLL than in advanced CLL 17 and that its expression is lower in patients with high-risk CLL. 16

Cited by 33 publications

References 29 publications

Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia

Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia

Waldenström′s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection

IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia

Contact Info

Product

Resources

About